Search results
Results from the WOW.Com Content Network
Non-peptide CCK B receptor antagonists such as L-365,260, L-369,293, YF-476, RP-69758, LY-288,513, PD-145,942 and the CCK B receptor inverse agonist L-740,093 have since been developed, [3] and while all of the drugs developed so far have suffered from limited bioavailability or other issues which have hindered their clinical development ...
Cholecystokinin receptors or CCK receptors are a group of G-protein coupled receptors which bind the peptide hormones cholecystokinin (CCK) and gastrin. [1] There are two different subtypes CCK A and CCK B which are ~50% homologous: [2] Various cholecystokinin antagonists have been developed and are used in research, although the only drug of this class that has been widely marketed to date is ...
A CDK (cyclin-dependent kinase) inhibitor is any chemical that inhibits the function of CDKs. They are used to treat cancers by preventing overproliferation of cancer cells . The US FDA approved the first drug of this type, palbociclib (Ibrance), [ 1 ] a CDK4 / 6 inhibitor, in February 2015, for use in postmenopausal women with breast cancer ...
CCK can be stimulated by a diet high in protein, or by protease inhibitors. [37] CCK has been shown to interact with orexin neurons, which control appetite and wakefulness . [38] CCK can have indirect effects on sleep regulation. [39]
Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist, [1] with fairly high selectivity for the CCK A subtype. [2]
CCK then acts on the gallbladder to release bile and on the pancreas to release digestive enzymes, which help to further break down the food. This coordinated response helps to ensure efficient digestion and absorption of nutrients. Another function is to act as a competitive inhibitor of trypsin, which is a protease that can activate other ...
CI-988 (PD-134,308) is a drug which acts as a cholecystokinin antagonist, selective for the CCK B subtype. In animal studies it showed anxiolytic effects [1] [2] and potentiated the analgesic action of both morphine [3] and endogenous opioid peptides, [4] [5] as well as preventing the development of tolerance to opioids [6] [7] and reducing symptoms of withdrawal.
Cyclin-dependent kinase inhibitor proteins work by inactivating the CDKs through degradation. The typical inactivation mechanism of the CDK/Cyclin complex is based on binding a CDK inhibitor to the CDK cyclin complex and a partial conformational rotation of the CDK. [4] The cyclin is thus forced to release the T loop and detach from the CDK.